Media thread, page-19

Yes, a good time in a general market malaise to remind ourselves of the outstanding company fundamentals :

All of CardieX’s products and product development activity are founded in our core arterial waveform technology - known globally as “SphygmoCor®”. Our SphygmoCor® technology currently has more than 4,500 installations worldwide and is used by leading research and pharmaceutical companies, such as Bayer, AstraZeneca, GSK as well as other leading healthcare institutions. CardieX is the only company that has FDA clearance for measuring central blood pressure, arterial stiffness, and other proprietary cardiovascular and arterial health parameters noninvasively in all adult subjects.

The ATCOR division continues to deliver, while the CONNEQT division is still hunting for it's mojo.

Some thoughts on the "imminent" quarterly ( he says tongue in cheek ) in regards ATCOR :

i) the last quarterly alluded to a smaller than expected cash receipts based on timing of receipts from clinical trials & related contracts. Expecting closer to $1m+ in cash receipts this quarter.
2) Has there been an R&D rebate and I've missed it ? I assume that most of the $2M spend on R&D last financial year was in Australia, and can have the 43.5% R&D Tax incentive applied ... another $1M cash.

... and on cash musings in the quarterly...

so in theory, $1.4M cash at start of quarter, plus $8M from the options exercise and $2M outlined above ... $11.4M cash, less $3M cash burn with extra activity, hires etc leading into product launches ... ~$8.4M left in the bank. I'm guessing a cash injection from an interested US institution in April/May is in the works once OTCQX/Consolidation is put to bed, and looking for Conneqt Pulse to start adding to receipts in Q4FY22 in cash flow projections.

IMO.
GLTAH